## OIP E SC 27 2003 27

## SEQUENCE LISTING

<110> Elan Pharmaceuticals, Inc.

Pharmacia & Upjohn Company

Varghese, John

Maillard, Michel

Beck, James

Baldwin, Eric

Hughes, Robert

Pulley, Shon

TenBrink, Ruth

- <120> Acetyl 2-Hydroxy-1,3-Diaminoalkanes
- <130> 02-793-C
- <140> 10/658,959
- <141> 2003-09-10
- <150> 60/409,453
- <151> 2002-09-10
- <150> 60/452,231
- <151> 2003-03-05
- <150> 60/491,757
- <151> 2003-08-01
- <160> 9

```
<170> PatentIn version 3.0
<210> 1
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-terminal biotin
<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> covalent attachment of oregon green
<400> 1
Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys Lys
<210> 2
 <211> 13
 <212> PRT
 <213> Artificial Sequence
 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> N-terminal biotin
```

```
<221> MISC_FEATURE
<222> (11)..(11)
<223> covalent attachment of oregon green
<400> 2
Ser Glu Val Lys Met Asp Ala Glu Phe Arg Cys Lys Lys
<210> 3
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-terminal biotin
<220>
<221> MISC_FEATURE
<222> (20)..(20)
 <223> covalent attachment of oregon green
 <400> 3
 Gly Leu Asn Ile Lys Thr Glu Glu Ile Ser Glu Ile Ser Tyr Glu Val
                5
 Glu Phe Arg Cys Lys Lys
 <210> 4
 <211> 34
 <212> PRT
 <213> Artificial Sequence
```

```
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-terminal biotin
<220>
<221> MISC_FEATURE
<222> (32)..(32)
<223> covalent attachment of oregon green
<400> 4
Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile
Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys
Lys Lys
<210> 5
<211> 33
<212> PRT
<213> Artificial Sequence
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-terminal biotin
<220>
<221> MISC_FEATURE
<222> (7)..(7)
```

<223> oxidized cysteine

```
<220>
<221> MISC_FEATURE
      (19)..(19)
<222>
<223> oxidized cysteine
<220>
<221> MISC_FEATURE
<222>
      (31)..(31)
<223> covalent attachment of oregon green
<400> 5
Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala Cys Lys
Lys
<210>
<211> 33
<212> PRT
<213> Artificial Sequence
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-terminal biotin
<400> 6
Cys Gly Gly Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu
Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu
```

Page 5

20 25 30

Phe

<210> 7

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<400> 7

Cys Gly Gly Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu 1 5 10 15

Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Asn Leu 20 25

<210> 8

<211> 9

<212> PRT

<213> Artificial Sequence

<400> 8

Ser Glu Val Asn Leu Asp Ala Glu Phe 1 5

<210> 9

<211> 30

<212> PRT

<213> Artificial Sequence

<400> 9

Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile 1 . 5 10 15

Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe 20 25 30